Market Intelligence, Clinical Progress, and High-Purity Reagents for MAP2K7-Targeted Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MAP2K7 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MAP2K7 (MKK7) Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for kinase assays and binding kinetics. |
View MAP2K7 Products |
| Gene Delivery | MAP2K7 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and JNK pathway reporter assays. |
View MAP2K7 Products |
| Benchmark Ab | Anti-MAP2K7 Recombinant Antibody High-specificity positive control for Western Blot, IP, and intracellular flow cytometry. |
View MAP2K7 Products |
| Validator | MAP2K7 siRNA Set Target-specific knockdown verification to validate phenotypic dependency. |
View MAP2K7 Products |
| Related Target A | MAP2K4 (MKK4) Parallel dual-specificity kinase activating the JNK pathway; critical for counter-screening and selectivity profiling. |
View MAP2K4 Products |
| Related Target B | MAPK8 (JNK1) Direct downstream substrate of MAP2K7; essential for functional kinase activity validation. |
View MAPK8 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling against parallel MAP2Ks (e.g., MAP2K4) | High-purity human MAP2K7 and MAP2K4 ortholog proteins strictly verified by mass spectrometry and sequence analysis. |
| Covalent inhibitor binding kinetics (e.g., targeting Cys218) | Intact, native-state recombinant proteins with verified sequence integrity, optimized for SPR/BLI binding assays. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and positive control antibodies included in the catalog. |
| False Positives in Phenotypic Screens | Pre-designed and validated siRNA pools included for target-specific knockdown verification. |
Live MAP2K7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MAP2K7 therapeutics is intensifying, with major players shifting focus from broad-spectrum MAPK inhibitors to highly selective covalent and allosteric small molecules. As first-generation kinase inhibitors face challenges with off-target toxicities, the next wave of R&D is targeting the specific activation loop of MAP2K7 and utilizing PROTAC (Proteolysis Targeting Chimera) technology to achieve sustained pathway suppression in JNK-dependent malignancies and inflammatory disorders.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Covalent) | Academic Institutes, Biotech Startups | Solid Tumors (Pancreatic, Breast), Inflammatory Diseases | High-purity recombinant MAP2K7 for mass spec-based covalent adduct detection and SPR kinetics. |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | Refractory Cancers, Neurodegenerative Disorders | High-yield protein constructs for ternary complex formation assays (MAP2K7-Degrader-E3 Ligase). |
| Gene Therapy / RNAi | RNA Therapeutics Developers | Fibrotic Diseases, Acute Tissue Injury | Lentiviral delivery systems and target-specific siRNA sets for target validation in primary cells. |